Premium
Increased bleeding in HIV‐positive Haemophiliacs treated with antiretroviral protease inhibitors
Author(s) -
S. J. Stanworth,
Michael J. Bolton,
Colin W. Hay,
C. Shiach
Publication year - 1998
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1046/j.1365-2516.1998.00154.x
Subject(s) - haemophilia , medicine , protease , protease inhibitor (pharmacology) , haemophilia a , complication , human immunodeficiency virus (hiv) , von willebrand disease , gastroenterology , surgery , antiretroviral therapy , immunology , viral load , von willebrand factor , enzyme , platelet , biology , biochemistry
Seventeen HIV‐positive patients with congenital Haemophilia, one with von Willebrand’s disease, and one with acquired Haemophilia in remission, were treated with antiretroviral protease inhibitors. Clear increases in the frequency of bleeds or changes in the bleeding pattern were documented in 10 individuals taking HIV protease inhibitors. Blood product requirements were increased in eight individuals with severe Haemophilia over the 6 months after starting HIV protease inhibitors. Therapy with the HIV protease inhibitor was discontinued in two patients in whom the increased bleeding was severe. No haeostatic cause for the increased bleeding tendency could be identified. Patients with bleeding disorders should be warned about this potential complication of HIV protease inhibitor therapy, and should be closely monitored.